In an evaluation of over 200 breast cancers, patients with tumors containing greater than 15 FOXP3+ cells had decreased RFS (p = 0.04 HR 1.58, 95 % CI 1.01 to 2.47) and overall survival (OS) (p = 0.07, HR 1.62 95 % CI 0.96 to 2.74) [10]. This evidence concerns the gene FOXP3 and breast carcinoma.